Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dexcom Inc (NQ: DXCM )

69.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dexcom Inc

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
A discounted stock can present an opportunity when there's a quality business behind it. 
Via The Motley Fool
Looking Into DexCom's Recent Short Interest
Via Benzinga
Down More Than 50% From Its High, Is DexCom Stock a Buy?
Is DexCom's business in trouble, or could this be a great buying opportunity for investors? 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $3,600 Today
Via Benzinga
2 Beaten-Down Growth Stocks You Might Regret Not Buying
Their headwinds won't last forever. 
Via The Motley Fool
Is DexCom a Millionaire Maker?
The company's game-changing technology could improve the lives of hundreds of millions of patients. 
Via The Motley Fool
$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today
Via Benzinga
What the Options Market Tells Us About DexCom
Via Benzinga
Is DexCom a Millionaire Maker?
It isn't the most likely candidate to make someone a millionaire, but it's theoretically possible. 
Via The Motley Fool
NASDAQ:DXCM, a strong growth stock, setting up for a breakout.
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Down More Than 50%, Is DexCom Stock a Bargain Now?
Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market. 
Via The Motley Fool
2 Magnificent Growth Stocks Down 45% and 32% to Buy Right Now
Sometimes, a discounted stock can present a valuable opportunity. 
Via The Motley Fool
DexCom Is Great. Here's Why You Shouldn't Buy It.
Two key uncertainties make the prospect of buying it today riskier than is desirable. 
Via The Motley Fool
Uh-Oh! Alphabet Is Selling Its Stake in 2 Historically High-Flying Artificial Intelligence (AI) Stocks
These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the last two quarters. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Is DexCom a Millionaire-Maker Stock?
The stock has delivered superior returns in the past 19 years. 
Via The Motley Fool
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $38,000 Today
Via Benzinga
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
No need to break the bank to get in on these excellent companies. 
Via The Motley Fool
3 Reasons DexCom Looks Like a No-Brainer Buy Right Now
The stock isn't normally this cheap, and investors should take advantage. 
Via The Motley Fool
Jim Cramer Doesn't Like Carnival Right Now: Royal Caribbean Is 'The One You Want'
Royal Caribbean has "the best systems right now," Jim Cramer says. "It's got the best numbers. It's the one you want, not Carnival." 
Via Benzinga
Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device
The companies are now duking it out for a new population of CGM users. 
Via Investor's Business Daily
Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.
DEXCOM INC (NASDAQ:DXCM): a strong growth stock preparing for the next leg up?. 
Via Chartmill
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a prescription. Designed for people with Type 2 diabetes and prediabetes, Stelo... 
Via Benzinga
Decoding 18 Analyst Evaluations For DexCom
Via Benzinga
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
The company is upbeat on its upcoming Stelo launch. The CGM is geared to people who don't use insulin. 
Via Investor's Business Daily
Is It Time to Buy July's Worst-Performing S&P 500 Stocks?
These stocks took a dive recently, and that could spell opportunity. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the latest. 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq Look To Snap Best Win Streaks Of 2024
Stocks are taking a breather, with the S&P 500 Index and Nasdaq Composite Index firmly lower this afternoon after yesterday nabbing their eighth-straight gains and best win streaks of the year. 
Via Talk Markets
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.